We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Development of Next-Generation Biologics for Immune and Inflammatory Diseases

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Development of Next-Generation Biologics for Immune and Inflammatory Diseases"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Recent Amgen/AstraZeneca agreement highlights pharmaceutical industry’s interest in developing novel and innovative biologics, according to a new report from decision resources. It was found that big pharmaceutical companies are looking to partner with biotechnology companies for the innovation required for next-generation biologic agents to treat immune and inflammatory diseases.

According to Innovative R&D and Dealmaking Opportunities: Immune and Inflammatory Disease Biologics, the market for biological drugs that treat autoimmune and inflammatory diseases is lucrative and expected to grow from more than $24 billion in 2010 to more than $42 billion in 2017. Although current biological therapies for immune and inflammatory diseases have been successful and the market for diseases such as rheumatoid arthritis is crowded, opportunities for new drugs exist because of patients that are refractory to these therapies and unmet needs not addressed by current drugs.

An agreement between Amgen and AstraZeneca announced earlier this month highlights the industry’s continuing interest in developing novel and innovative biologics to treat immune and inflammatory diseases. Amgen and AstraZeneca will jointly develop and commercialize five of Amgen’s clinical-stage monoclonal antibodies.

“AstraZeneca is in urgent need of new drug candidates and this alliance demonstrates its commitment to replenishing its pipeline through an externalization strategy that includes in-licensing and partnering,” said Decision Resources Principal Analyst Barbara Bolten, M.S., M.B.A. “For Amgen, AstraZeneca provides commercialization experience for respiratory products and enables Amgen to offload significant development costs and redirect internal resources to other projects.”

Innovative R&D and Dealmaking Opportunities: Immune and Inflammatory Disease Biologics is a new report from Decision Resources. Through analysis of innovative areas of research and early-stage activities of smaller biotech companies, pharmaceutical business development and strategic planning teams can understand where key opportunities lie. Each report features a clinical development pipeline (Phase I-III) of novel drugs, a pipeline analysis and an overview of development programs by drug target or mechanism of action. Reports identify and highlight innovator companies that offer discovery, preclinical and clinical partnering opportunities. In addition, an analysis of recent corporate deals highlights current partnering and dealmaking strategies. Reports also include detailed information about the therapeutic area market landscape.